A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2225 in Healthy Participants
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs ACE 1334 (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme